Drexel, Heinz (2018). Cost-effectiveness with PCSK9 inhibitors: a matter of costs. European heart journal - cardiovascular pharmacotherapy, 4(1), pp. 23-24. Oxford University Press 10.1093/ehjcvp/pvx030
|
Text
pvx030.pdf - Published Version Available under License Publisher holds Copyright. Author holds Copyright Download (105kB) | Preview |
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology |
UniBE Contributor: |
Drexel, Heinz |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2055-6837 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Isabel Lorenz |
Date Deposited: |
20 Nov 2019 09:08 |
Last Modified: |
08 Dec 2022 12:25 |
Publisher DOI: |
10.1093/ehjcvp/pvx030 |
PubMed ID: |
29315397 |
BORIS DOI: |
10.48350/135340 |
URI: |
https://boris.unibe.ch/id/eprint/135340 |
Actions (login required)
 |
Edit item |